Kyverna Therapeutics, Inc.
Built from real-time financials and updated daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a KYTX research report →
Companykyvernatx.com
Kyverna Therapeutics, Inc. , a clinical-stage biopharmaceutical company, focuses on developing cell therapies for patients suffering from autoimmune diseases. Its lead product candidate is KYV-101, an autologous CD19 CAR T-cell product candidate for the treatment of patients with lupus nephritis and systemic sclerosis that is in Phase I clinical trial; and for myasthenia gravis and multiple sclerosis that is in Phase II clinical trial.
- CEO
- Warner Biddle
- IPO
- 2024
- Employees
- 112
- HQ
- Emeryville, CA, US
Price Chart
Valuation
- Market Cap
- $381.34M
- P/E
- -3.36
- P/S
- 0.00
- P/B
- 2.69
- EV/EBITDA
- -2.30
- Div Yield
- 0.00%
Profitability
- Gross Margin
- 0.00%
- Op Margin
- 0.00%
- Net Margin
- 0.00%
- ROE
- -81.87%
- ROIC
- -71.42%
Growth & Income
- Revenue
- $0 · 0.00%
- Net Income
- $-161,307,000 · -26.54%
- EPS
- $-3.64 · -9.31%
- Op Income
- $-169,827,000
- FCF YoY
- -32.00%
Performance & Tape
- 52W High
- $13.67
- 52W Low
- $2.16
- 50D MA
- $9.07
- 200D MA
- $7.37
- Beta
- 2.06
- Avg Volume
- 909.97K
Get TickerSpark's AI analysis on KYTX
Pro members can request AI-generated analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Start Free Trial →Recent Insider Transactions
| Date | Insider | Type | Shares |
|---|---|---|---|
| May 4, 26 | Dac Nadia | other | 300,000 |
| May 4, 26 | Dac Nadia | other | 0 |
| Mar 13, 26 | GRASSO MARC | other | 65,000 |
| Mar 13, 26 | GRASSO MARC | other | 10,000 |
| Mar 13, 26 | Biddle Warner Weston | other | 350,000 |
| Mar 13, 26 | Biddle Warner Weston | other | 58,000 |
| Mar 13, 26 | GEHCHAN NAJI | other | 105,000 |
| Mar 13, 26 | GEHCHAN NAJI | other | 18,000 |
| Feb 24, 26 | Miller Andrew Craig | other | 0 |
| Feb 24, 26 | Miller Andrew Craig | other | 42,945 |
Our KYTX Coverage
We haven't published any research on KYTX yet
For a full analyst-grade research report — grades, price targets, full financials, chart analysis — generate one on demand.
Generate KYTX Report →